Market Overview

PTC Therapeutic, Roche Announce Joint Program in Spinal Muscular Atrophy Enters First Stage of Clinical Development

Related PTCT
Biotech Enters Reporting Season With Large Caps Central To Sector Performance
PTC Therapeutics Initiates Confirmatory Phase 3 Clinical Trial of Translarna™ (ataluren) in Patients With Nonsense Mutation Cystic Fibrosis (nmCF)

PTC Therapeutics, Inc. (NASDAQ: PTCT), the SMA Foundation, and Roche (OTC: RHHBY), announced today that their joint research program in Spinal Muscular Atrophy (SMA) has entered the first stage of clinical development aiming to assess safety and tolerability of an oral compound in healthy volunteers. SMA is a genetic neuromuscular disorder that leads to muscle weakness and mobility impairment and is considered the leading genetic cause of death in infants and toddlers.   

See full press release

Posted-In: News Guidance Buybacks Global

 

Related Articles (RHHBY + PTCT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters